Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More

Spotlight

Editas News

July 1, 2015
Editas Medicine Appoints Andrew Hack, M.D., Ph.D., as Chief Financial Officer Read More

Publications & Abstracts

May 15, 2015
Therapeutic Editing of the HBB Locus Using the Endogenous HBD Locus as a Donor Template Read More

May 15, 2015
Staphyloccocus aureus Cas9 an alternative Cas9 for genome editing applications Read More

May 14, 2015
Characterization of Cas9-mediated genome editing in human T cells Read More

May 13, 2015
Biophysical Characterization and Direct Delivery of S. pyogenes Cas9 Ribonucleoprotein Complexes  Read More

May 13, 2015
Cas9-mediated genome editing in hematopoietic stem/progenitor cells  Read More